How is XBiotech Inc. (NASDAQ:XBIT) Executing its Strategy?


XBiotech Inc. (NASDAQ:XBIT) stock had a weekly volatility of 65.32% and a monthly volatility of 22.53%. XBiotech Inc. XBIT shares float stands at 19.26M.

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

Recently, XBiotech Inc. (NASDAQ:XBIT) reported that XBiotech Inc. quarterly Return on Assets is -65.10%%, while quarterly Return on Equity was -71.80%.


The firm’s stock 50-Day High is $-76.74% and a 50-Day Low of $51.62%. 20-Day Simple Moving Average was $-50.32% while 50-Day SMA was $-62.94%.

The firm announced EPS of $-1.63. This shows an EPS growth quarter over last quarter was 0.10%. EPS for the year was $-33.80%.

The firm’s monthly average volume for the reported quarter was 402.08K and 402.08K for the full fiscal year. The relative volume was 35.07 for the quarter and 35.07 for the full fiscal year.

The stock’s 50-Day High in the last quarter was $-76.74% while the 50-Day Low was $51.62%. In the last fiscal year, the stock hit a 52-Week High of $-83.20% and a 52-Week Low of $51.62%.

The firm’s insider ownership was 17.80% and institutional ownership was 17.10%. Total institutional transactions amounted to 2.39%.

XBiotech Inc. (NASDAQ:XBIT) announced that an Independent Data Monitoring Committee (IDMC) has performed its second prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company’s novel candidate antibody therapy for the treatment of colorectal cancer. The IDMC had no safety concerns from the unblinded analysis. However, the committee recommended the early termination of the study since the findings were not sufficient to meet efficacy or the threshold for continuation, which involved a prospectively defined acceptance boundary for the interim analysis of less than or equal to p = 0.08.